A biopharmaceutical company focused on developing and commercializing treatments for sleep disorders, particularly narcolepsy. Its lead product, Lumryz, is an extended‑release sodium oxybate approved in the U.S. for treating excessive daytime sleepiness and cataplexy in narcolepsy patients. Investor...
No congressional trades have been disclosed for Avadel Pharmaceuticals PLC (AVDL) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
No congressional trades found for this stock.